Chronic Lyme and Cannabis: What Long-Haul Patients Need to Know

Cannabinoid Modulation and PTLDS

For the high-functioning professional, Post-Treatment Lyme Disease Syndrome (PTLDS) often acts as a neurological roadblock. The persistence of Borrelia burgdorferi—even after standard antibiotic courses—can leave behind a state of chronic neuroinflammation. When the blood-brain barrier is compromised, executive function and data processing capabilities may suffer.

The endocannabinoid system (ECS) provides a biological framework that may support the mitigation of these deficits through strategic modulation.

Neuroinflammation and the Cytokine Response

Borrelia infection can trigger a systemic pro-inflammatory cascade. In the central nervous system, this may manifest as an overproduction of cytokines, specifically IL-6 and TNF-alpha. These proteins can disrupt synaptic transmission, leading to cognitive fatigue. Cannabinoids may act as modulators, utilizing CB1 and CB2 receptor signaling to support the regulation of this immune response.

CBG: A Strategic Cannabinoid

Cannabigerol (CBG) is a non-psychoactive ligand that targets the α2-adrenoceptor and acts as an antagonist at the 5-HT1A receptor.

• GABA Regulation: CBG may inhibit GABA reuptake. By supporting GABA availability, it can promote focus and stress management without the sedation associated with some pharmaceutical anxiety medications.
• Neuroprotection: CBG may help mitigate oxidative stress within neurons, supporting the myelin sheath and promoting neuronal health, which is relevant for individuals experiencing PTLDS-related cognitive decline.

Managing the Jarisch-Herxheimer Reaction

Aggressive antibiotic protocols can induce a Jarisch-Herxheimer ("Herx") reaction—a systemic inflammatory surge caused by the release of endotoxins.

• Cytokine Regulation: Cannabinoids may assist in supporting the immune system’s response to this cytokine surge.
• Nausea Control: For professionals, gastrointestinal distress can be a significant barrier to productivity. Low-dose THC (1-2mg) may help manage nausea without inducing significant cognitive impairment.

Terpene Synergy for Cognitive Clarity

Volatile aromatic compounds known as terpenes can influence how cannabinoids interact with the brain.

1. Alpha-Pinene: Acts as an acetylcholinesterase inhibitor. By slowing the breakdown of acetylcholine, it may bolster memory and sustained attention.
2. Limonene: Facilitates dopaminergic modulation. It may support dopamine and serotonin levels in the prefrontal cortex, which is useful for mood stability during sensory overload.
3. Beta-Caryophyllene: A sesquiterpene that binds to CB2 receptors. It provides peripheral anti-inflammatory support for joint pain and neuropathy without cerebral activity.

Precision Dosing for the Professional Schedule

Predictable, metered administration is necessary for those managing PTLDS while maintaining a professional workload.

• Daytime Stabilization (Sublingual): A 20mg CBD, 10mg CBG, and 1mg THC ratio. Sublingual delivery bypasses first-pass metabolism, offering a four to six-hour window of support for pain management and focus.
• Acute Cognitive Recovery (Vaporization): Utilizing dry herb vaporization at 355°F (180°C) preserves delicate terpenes like Terpinolene and Ocimene. This low-temp method provides support for light sensitivity and afternoon fatigue without combustion byproducts.
• Nocturnal Glymphatic Support (Oral): A 5mg THC to 5mg CBN ratio. CBN may promote REM sleep, supporting the glymphatic system in its role of flushing metabolic waste from the brain.

TRP Channels and Neuropathy

Lyme-related nerve pain is often mediated by TRPV1 (vanilloid) receptors, which regulate thermal sensitivity and pain signaling. Consistent use of CBD and CBG may assist in desensitizing these receptors, supporting a higher threshold for chronic burning sensations or "electric shock" pains in the extremities.

Professional Implementation

Managing PTLDS in a corporate environment requires discretion and awareness of local regulations.

• Topicals: High-potency THC/CBD balms offer targeted relief for joint inflammation without systemic entry.
• Microdosing: Staying under the 3mg THC threshold helps ensure that the benefits of cannabinoid synergy are realized while minimizing the risk of impairment.

When addressing PTLDS, the objective is to harmonize the ECS to support baseline cognitive function. By leveraging specific cannabinoids and terpenes, individuals may navigate the residual effects of Lyme disease with improved mental acuity and physical comfort.

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed

2. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Claro E, Di Marzo V, Izzo AA. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 85(9):1306-16. PubMed

3. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 1(7):1333-49. PubMed

4. Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA. (2014). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther. 39(5):564-6. PubMed

5. Mlost J, Bryk M, Starowicz K. (2020). Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 21(22):8870. PubMed